ImmunoGen, Inc. (IMGN) has a consensus analyst rating of Hold, based on 22 analysts covering the stock. Of those, 6 recommend buying, 15 recommend holding, and 1 recommend selling.
The analyst consensus price target for IMGN is $14.79, representing a -52.6% downside from the current price of $31.235. Price targets range from a low of $6.36 to a high of $22.00.
